Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2018
Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2018. Glenmark recalls 100,000 bottles of drug over incorrect instrictions
The ongoing nationwide voluntary recall is a class III recall Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 025250 Name of the Signatory :- Mr. Harish KuberDesignation :- Company Secretary and Compliance Officer Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2018
Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2018 Glenmark, Helsinn Group tie up for sale of anti-emetic drug in India, Nepal
Glenmark Pharmaceuticals today said it has signed a licensing agreement with Swiss pharma player Helsinn Group to introduce Akynzeo' in India and N Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub:- Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement for launch of AKYNZEO in India and Nepal Glenmark gets USFDA nod for psoriasis spray
Glenmark Pharmaceuticals has received final nod from the US health regulator for its Clobetasol Propionate spray used for the treatment of moderate to severe plaque psoriasis in adults.Gle Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub:- Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05% Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub:- Glenmark Pharmaceuticals Presents New Data on Ryaltris, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress Announcement under Regulation 30 (LODR)-Credit Rating
Sub:- Rating by S&P; Global Ratings With reference to the above subject, we have to inform you that our credit rating has been revised by S&P; Global Ratings from 'BB' to 'BB-' as part of their review cycle. They have revised the outlook from 'Negative' to 'Stable'. In addition, they have revised the rating on the senior unsecured notes issued in 2016 from 'BB' to 'BB-'. Kindly find enclosed rating research update issued by S&P; Global for your reference.